Prostate Cancer – Canada Drug Forecast and Market Analysis

Pages: 165 Published: December 01, 2012 Report Code: GDHC1028CFR

  • Overview
  • Contents
  • Tables
  • Figures
  • Listen
    iSpeech

GlobalData has released its new Country report, “Prostate Cancer – Canada Drug Forecast and Market Analysis”. The recent approvals of second-line metastatic castration-resistant prostate cancer (mCRPC) therapies like J&J’s Zytiga (abiraterone acetate) and Medivation/Astellas’ Xtandi (enzalutamide) will drive strong market growth over the next decade. These safe and orally administered treatments will provide safety and convenience benefits over the current standard of care, chemotherapy with docetaxel, while prolonging the overall survival of patients with mCRPC. The December 12, 2012 FDA approval of Zytiga for the added indication of chemotherapy-naïve mCRPC marks the onset of a new treatment paradigm for the disease, in which chemotherapy is relegated to second-line therapy and beyond. For patients with earlier-stage prostate cancer, androgen deprivation therapy with LHRH agonists and first-generation antiandrogens remains the standard of care for suppressing testosterone levels and temporarily controlling the disease.

In Canada, prostate cancer is diagnosed following an abnormal DRE, elevated PSA levels detected during routine screening, or a patients’ presentation with symptoms that leads to either of these tests. A suspected diagnosis of prostate cancer is confirmed by TRUS-guided multiple core needle biopsies, and bone metastases are detected using a CT scan or bone scan. The uptake of routine PSA screening has been high in Canada, but some Canadian physicians surveyed by GlobalData reported that they plan to decrease their use of routine screening in response to the recent USPSTF recommendation against it (Baade et al., 2009).

Scope

Overview of Prostate Cancer, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

Detailed information on the key drugs in Canada including product description, safety and efficacy profiles as well as a SWOT analysis.

Sales forecast for the top drugs in Canada from 2012 to 2022.

Analysis of the impact of key events as well the drivers and restraints affecting the Canada Prostate cancer market.

Reasons to Buy

Understand and capitalize by identifying products that are most likely to ensure a robust return

Stay ahead of the competition by understanding the changing competitive landscape for Prostate cancer

Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

Make more informed business decisions from insightful and in-depth analysis of Prostate cancer drug performance in Canada

Obtain sales forecast from 2012-2022 in Canada

Table of Contents

1 Table of Contents 4

1.1 List of Tables 7

1.2 List of Figures 9

2 Introduction 10

2.1 Catalyst 10

2.2 Related Reports 10

2.3 Upcoming Related Reports 12

3 Disease Overview 13

3.1 Etiology and Pathophysiology 13

3.1.1 Etiology 13

3.1.2 Pathophysiology 13

3.1.3 Prognosis 14

3.1.4 Quality of Life 15

3.2 Symptoms 15

4 Disease Management 16

4.1 Diagnosis and Referral Overview 16

4.2 Treatment Overview 18

4.2.1 Conservative Management Strategies 22

4.2.2 Localized Treatments 23

4.2.3 Hormone Therapy 24

4.2.4 Drug Therapies 26

4.3 Canada 27

4.3.1 Diagnosis 27

4.3.2 Clinical Practice 27

5 Competitive Assessment 29

5.1 Overview 29

5.2 Strategic Competitor Assessment 30

5.3 Product Profiles – Major Brands, Hormone Therapies 33

5.3.1 Zoladex (goserelin acetate) 33

5.3.2 Lupron Depot (leuprolide acetate) 36

5.3.3 Eligard (leuprolide acetate) 39

5.3.4 Trelstar (triptorelin acetate) 44

5.3.5 Firmagon (degarelix) 47

5.3.6 Casodex (bicalutamide) 50

5.4 Product Profiles – Major Brands, Chemotherapies 53

5.4.1 Taxotere (docetaxel) 54

5.4.2 Jevtana (cabazitaxel) 57

5.5 Product Profiles – Major Brands, Therapeutic Vaccines 60

5.5.1 Provenge (sipuleucil-T) 61

5.6 Product Profiles – Major Brands, Targeted Therapies 65

5.6.1 Zytiga (abiraterone acetate) 66

5.6.2 Xtandi (enzalutamide) 69

5.7 Product Profiles – Major Brands, Bone Therapies 73

5.7.1 Xgeva (denosumab) 74

5.7.2 Zometa (zoledronic acid) 77

5.8 Other Marketed Hormone and Drug Therapies 80

6 Opportunity and Unmet Need 81

6.1 Overview 81

6.2 Efficacy at Prolonging Overall Survival 82

6.3 Safety 82

6.4 Mitigation of Symptoms 83

6.5 Cost 83

6.6 Convenient Routes of Administration 83

6.7 Accurate Diagnostic Tests and Surveillance Tools 84

6.8 Unmet Needs Gap Analysis 84

6.9 Opportunity: Targeting Early-Stage, Hormone-Sensitive Prostate Cancer 86

7 Pipeline Assessment 87

7.1 Overview 87

7.2 Promising Drugs in Clinical Development 88

7.2.1 Cabozantinib 90

7.2.2 Custirsen Sodium 94

7.2.3 Sprycel (dasatinib) 99

7.2.4 Yervoy (ipilimumab) 103

7.2.5 Orteronel 108

7.2.6 Alpharadin (radium-223 chloride) 112

7.2.7 Tasquinimod 117

7.2.8 ProstVac (Vaccinia-PSA-TRICOM/Fowlpox-PSA-TRICOM) 121

8 Market Outlook 126

8.1 Canada 126

8.1.1 Forecast 126

8.1.2 Key Events 129

8.1.3 Drivers and Barriers 129

9 Appendix 131

9.1 Bibliography 131

9.2 Abbreviations 144

9.3 Methodology 147

9.4 Forecasting Methodology 147

9.4.1 Number of Prostate Cancer Patients Currently Seeking Treatment 147

9.4.2 Percent Drug-treated Patients 148

9.4.3 Percent Hormone Therapy-Treated Patients 148

9.4.4 Drugs Included in Each Therapeutic Class 148

9.4.5 General Pricing Assumptions 149

9.4.6 Individual Drug Assumptions 151

9.4.7 Generic Erosion 159

9.4.8 Pricing of Pipeline Agents 159

9.5 Physicians and Specialists Included in This Study 160

9.6 Survey of Prescribing Physicians 162

9.7 About the Authors 163

9.7.1 Authors 163

9.7.2 Global Head of Healthcare 164

9.8 About GlobalData 165

9.9 Contact Us 165

9.10 Disclaimer 165

List of Tables

Table 1: Stage Distribution of Prostate Cancer at Diagnosis in Selected Major Markets 14

Table 2: Global Variations in Recommendations on Routine PSA Screening 16

Table 3: Most Commonly Followed Treatment Guidelines for Prostate Cancer, 2012 19

Table 4: Most Commonly Prescribed Drugs for Prostate Cancer by Class in the Global Markets,

2012 21

Table 5: Leading Treatments for Prostate Cancer, 2012 32

Table 6: Product Profile – Zoladex 34

Table 7: Zoladex SWOT Analysis, 2012 36

Table 8: Product Profile – Lupron Depot 37

Table 9: Lupron Depot SWOT Analysis, 2012 39

Table 10: Product Profile – Eligard 41

Table 11: Eligard SWOT Analysis, 2012 43

Table 12: Product Profile – Trelstar 45

Table 13: Trelstar SWOT Analysis, 2012 46

Table 14: Product Profile – Firmagon 47

Table 15: Firmagon SWOT Analysis, 2012 49

Table 16: Product Profile – Casodex 51

Table 17: Casodex SWOT Analysis, 2012 53

Table 18: Product Profile – Taxotere 55

Table 19: Taxotere SWOT Analysis, 2012 57

Table 20: Product Profile – Jevtana 58

Table 21: Jevtana SWOT Analysis, 2012 60

Table 22: Product Profile – Provenge 61

Table 23: Provenge SWOT Analysis, 2012 65

Table 24: Product Profile – Zytiga 67

Table 25: Zytiga SWOT Analysis, 2012 69

Table 26: Product Profile – Xtandi 71

Table 27: Xtandi SWOT Analysis, 2012 73

Table 28: Product Profile – Xgeva 75

Table 29: Xgeva SWOT Analysis, 2012 77

Table 30: Product Profile – Zometa 78

Table 31: Zometa SWOT Analysis, 2012 80

Table 32: Summary of Other Marketed Hormone and Drug Therapies, 2012 80

Table 33: Overall Unmet Needs, Hormone-Sensitive Prostate Cancer – Current Level of

Attainment 81

Table 34: Overall Unmet Needs, CRPC – Current Level of Attainment 82

Table 35: Clinical Unmet Needs – Gap Analysis, 2012 85

Table 36: Prostate Cancer – Phase III Pipeline, 2012 88

Table 37: Comparison of Therapeutic Classes in Development for Prostate Cancer, 2012 88

Table 38: Product Profile – Cabozantinib 90

Table 39: Cabozantinib SWOT Analysis, 2012 94

Table 40: Product Profile – Custirsen Sodium 95

Table 41: Custirsen Sodium SWOT Analysis, 2012 98

Table 42: Product Profile – Sprycel 99

Table 43: Sprycel SWOT Analysis, 2012 103

Table 44: Product Profile – Yervoy 104

Table 45: Yervoy SWOT Analysis, 2012 108

Table 46: Product Profile – Orteronel 109

Table 47: Orteronel SWOT Analysis, 2012 112

Table 48: Product Profile – Alpharadin (radium-223 chloride) 113

Table 49: Alpharadin SWOT Analysis, 2012 116

Table 50: Product Profile – Tasquinimod 117

Table 51: Tasquinimod SWOT Analysis, 2012 120

Table 52: Product Profile – ProstVac (Vaccinia-PSA-TRICOM/Fowlpox-PSA-TRICOM) 121

Table 53: ProstVac SWOT Analysis, 2012 125

Table 54: Sales Forecasts ($m) for Prostate Cancer in Canada, 2012-2022 127

Table 55: Key Events Impacting Sales for Prostate Cancer in Canada, 2012-2022 129

Table 56: Prostate Cancer Market in Canada – Drivers and Barriers, 2012 129

Table 57: Physicians Surveyed, By Country 162

List of Figures

Figure 1: General Treatment Algorithm for Prostate Cancer, 2012 20

Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Prostate Cancer, 2012-

2022 89

Figure 3: Sales for Prostate Cancer in Canada by Drug Class, 2012-2022 128

$4995

Can be used by individual purchaser only

$14985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 (0) 20 7947 2960

GDPR + CCPA Compliant

Personal and transaction information are kept safe from unauthorised use.

Recently Viewed Reports

Looking to stay on top of industry & market trends?

Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.